BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BSP - Biological Signal Processing Ltd. Biological Signal Processing Ltd Presents Clinical Results At The ISCE Conference In Florida, US


10/19/2005 5:11:05 PM

HUTCHINSON ISLAND, Fla., April 28 /PRNewswire/ -- BSP, developing superior electrocardiograph (ECG) technology with breakthrough diagnostic value for detecting and monitoring ischemic heart diseases (IHD), will be presenting study results conducted with its HyperQ(TM) system, at the International Society for Computerized Electrocardiology (ISCE) 2004 in Florida.

The study, titled "High Frequency Mid-QRS Analysis (HyperQ(TM)) - an Effective Tool for the Monitoring and Diagnosis of Myocardial Ischemia", validates the high diagnostic efficacy of the HyperQ(TM) score for detecting and monitoring ischemic heart disease, far surpassing that of the standard stress ECG, using SPECT nuclear mapping as the gold standard.

One of the more important results that will be presented at the conference relates to a specific sub-population of patients, where expert cardiologists disagreed on the interpretation of conventional ECG readings. For this group, the HyperQ(TM) system demonstrated remarkable results, correctly identifying all non-ischemic subjects (100% specificity) and all ischemic patients (100% sensitivity). The study findings will also appear in a publication at the JEC - Journal of Electrocardiology, following the conference presentation.

A list of previous scientific references underscoring the technology implemented in BSP's system could be found at: http://www.bsp.co.il/publications.shtm.

BSP was founded in 2000 by Dr. Amir Beker, CEO, a graduate of the prestigious 'Talpiot' program of the Israeli Air Force, and a PhD in Medical Physics.

For more information, please visit us at http://www.bsp.co.il/ or contact info@bsp.co.il.

Contact: Yuval Raviv, Vice President, +972-3-6474840, yuval@bsp.co.il Dr. Amir Beker, CEO, amir@bsp.co.il

BSP Biological Signal Processing Ltd

CONTACT: Yuval Raviv, Vice President, +972-3-6474840, yuval@bsp.co.il,or Dr. Amir Beker, CEO, amir@bsp.co.il, both of BSP Biological SignalProcessing Ltd



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES